Refractory epilepsy in dogs remains a frontline clinical challenge
Bottom line
Veterinary Practice News has put a spotlight on refractory, or drug-resistant, epilepsy in dogs, underscoring a point many general practitioners already know from experience: for a subset of patients, seizure control remains difficult even with appropriate antiseizure therapy. The article, authored by neurologist Simon Platt and published through the outlet’s Education Center with support from PRN Pharmacal, argues that clinicians should aim for complete seizure control when possible, while also reassessing why a dog may not be responding, including diagnosis, disease progression, breed-related risk, treatment adherence, and comorbidities. It also points to adjunct strategies such as medium-chain triglyceride-enriched diets and, in select cases, nonpharmacologic options. (veterinarypracticenews.com)
Why it matters: Refractory epilepsy carries a substantial quality-of-life burden for dogs, pet parents, and care teams, and it often forces primary care veterinarians to balance urgency, expectations, monitoring, and referral decisions. Consensus guidance from the International Veterinary Epilepsy Task Force has long emphasized structured diagnosis and treatment pathways, including when to pursue MRI and CSF analysis in dogs with red flags or apparent drug resistance. Cornell notes that roughly 20% of dogs have refractory epilepsy and may require more than one antiepileptic medication. At the same time, the treatment landscape is still evolving, including the FDA’s January 21, 2026 full approval of KBroVet, a potassium bromide chewable for seizures associated with idiopathic epilepsy in dogs. (pmc.ncbi.nlm.nih.gov)
What to watch: Expect continued attention on earlier identification of true drug resistance, multimodal management, and how newly fully approved therapies and diet-based interventions are incorporated into everyday practice. (fda.gov)
A new Veterinary Practice News education feature is drawing attention to one of small animal neurology’s most frustrating realities: some dogs keep seizing despite treatment. In “Why Some Dogs Keep Seizing: Understanding and Managing Refractory Epilepsy,” neurologist Simon Platt outlines the clinical challenge of refractory, or drug-resistant, epilepsy and argues that the profession should keep complete seizure control as the goal, even when that goal is hard to reach. The piece was published through the outlet’s sponsored Education Center and supported by PRN Pharmacal. (veterinarypracticenews.com)
The topic lands at a time when canine epilepsy management is getting fresh attention from both clinicians and industry. The International Veterinary Epilepsy Task Force established a framework years ago for diagnosing idiopathic epilepsy, defining treatment goals, and identifying when a case needs deeper workup or escalation. Those recommendations remain central because “refractory” cases can reflect several different problems: an incomplete diagnostic picture, structural disease missed early, inadequate dosing, poor tolerability that limits dose escalation, pet parent adherence challenges, or genuine pharmacoresistance. IVETF guidance specifically recommends advanced imaging and CSF analysis in dogs with certain red flags, including dogs with presumed idiopathic epilepsy that become drug-resistant on a single antiseizure medication titrated to the highest tolerable dose. (pmc.ncbi.nlm.nih.gov)
Platt’s article highlights that drug resistance is not just a medication problem. It may relate to seizure etiology, disease progression, and breed effects, which is consistent with the broader literature and consensus guidance suggesting genetic and breed-linked factors may influence treatment success. The article also points to adjunctive management beyond conventional drug changes, including dietary strategies. That aligns with published evidence showing that medium-chain triglyceride, or MCT, dietary interventions can improve seizure control in some dogs with idiopathic epilepsy, including in randomized controlled trials and multicenter studies. (veterinarypracticenews.com)
There’s also a timely regulatory backdrop. On January 21, 2026, the FDA granted full approval to KBroVet, a potassium bromide chewable tablet for control of seizures associated with idiopathic epilepsy in dogs. FDA said the product had first received conditional approval in January 2021 and that Pegasus Laboratories generated the effectiveness data needed for full approval after four annual renewals. The agency also stressed that the drug is prescription-only and requires close veterinary oversight, including monitoring for bromide intoxication and avoiding abrupt diet changes that could affect bromide handling and seizure control. (fda.gov)
Direct outside commentary on the Veterinary Practice News article itself was limited, but the broader expert view is consistent: refractory epilepsy is common enough to shape day-to-day primary care decision-making. Cornell’s Riney Canine Health Center says approximately 20% of dogs have refractory epilepsy and require more than one antiepileptic medication. That helps explain why neurology referral pathways, therapeutic drug monitoring, emergency plans for cluster seizures, and realistic counseling for pet parents remain such important parts of care. (vet.cornell.edu)
Why it matters: For veterinary professionals, the practical takeaway is that persistent seizures should trigger a systematic rethink, not just another medication add-on. Cases labeled “refractory” may need confirmation of seizure type and cause, review of serum drug levels and adherence, reconsideration of diet and concurrent medications, and a lower threshold for advanced diagnostics or neurology referral. The newer regulatory validation around potassium bromide may give clinicians added confidence in one longstanding option, but it doesn’t change the need for individualized plans and careful monitoring. In parallel, the evidence for MCT-based nutritional support suggests that multimodal management can be more than a last resort; in some dogs, it may be a meaningful part of earlier case optimization. (fda.gov)
Another important layer is communication. Refractory epilepsy can quickly become a workforce and workflow issue inside practice, with repeated urgent calls, after-hours triage, medication questions, and emotionally exhausted pet parents. IVETF guidance notes the broader daily-life burden of canine epilepsy on households, and that burden often lands first in general practice. Clear seizure action plans, documented thresholds for emergency care, and early expectation-setting about what “control” means can help teams manage both patient risk and client distress. (pmc.ncbi.nlm.nih.gov)
What to watch: The next phase to watch is how practices integrate fully approved bromide therapy, evidence-based diet strategies, and earlier referral or advanced diagnostics into more standardized care pathways for dogs whose seizures persist after first-line treatment. (fda.gov)